Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...
H.C. Wainwright notes that Neutral-rated Cassava Sciences (SAVA) has announced its financial and operational results for the fiscal year ended ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback